Precise Deposition of Polydopamine on Cancer Cell Membrane as Artificial Receptor for Targeted Drug Delivery

HIGHLIGHTS
Polydopamine (PDA) generation catalyzed using G-quadruplex DNAzyme
TME high K⁺ and H₂O₂ employed to produce PDA only on cancerous cells membrane
PDA generated and deposited on cancerous cells and acted as artificial receptors
PDA artificial receptors facilitated targeted delivery of drugs with amino groups
Precise Deposition of Polydopamine on Cancer Cell Membrane as Artificial Receptor for Targeted Drug Delivery

Hoda Safari Yazd,1,4 Yu Yang,2,3,4 Long Li,1 Lu Yang,1 Xiaowei Li,1 Xiaoshu Pan,1 Zhuo Chen,2 Jianhui Jiang,2 Cheng Cui,2 and Weihong Tan2,3,5,*

SUMMARY
Compared with conventional chemotherapy and radiotherapy, targeted molecular therapy, e.g., antibody-drug conjugates or aptamer-drug conjugates, can specifically identify overexpressed natural receptors on the cancer cell, perform targeted release of anticancer drugs, and achieve targeted killing of tumor cells. However, many natural receptors are also expressed on non-cancer cells, thereby diverting the targeting molecules to healthy cells. By generating artificial cell surface receptors specific to diseased cells, aptamer-drug conjugates can identify these artificial receptors, improve therapeutic efficacy, and decrease the minimum effective dosage. In this study, we use high K+ and high H2O2 of the tumor microenvironment (TME) to produce polydopamine only on living cancer cell membrane. Owing to the significant reactivity of polydopamine with amino groups, e.g., the amino group of proteins, polydopamine can deposit on tumor cells and act as “artificial receptors” for targeted delivery of anticancer drugs with amino groups, in other words, amino-containing drugs and protein drugs.

INTRODUCTION
Current cancer therapy, such as anticancer chemotherapeutic drugs or radiation therapy, mostly cannot differentiate healthy from cancer cells owing to a lack of selectivity (Yang et al., 2016). Targeted drug delivery systems, on the other hand, promise to extend the therapeutic impact of drugs by enhancing delivery to the targeted tissue, increasing target/nontarget tissue ratio, avoiding nonspecific toxicity in healthy tissues, and reducing side effects. Targeted drug delivery can reduce drug dosage and the accompanying drug toxicity, as well as enhance therapeutic efficiency at equivalent plasma concentrations (Chari, 2008; Yang et al., 2018). To this end, several molecular targeting elements such as nucleic acid scaffolds, antibodies, and small organic molecules with recognition ability to diseased cells have been extensively investigated. Most recently, aptamers, which are single-stranded nucleic acid ligands selected by Systematic Evolution of Ligands by Exponential Enrichment (SELEX), have been developed as a novel family of molecules that rival antibodies in both diagnostic and therapeutic applications (Zhu et al., 2015; Xuan et al., 2018; Li et al., 2019). Aptamers are highly specific with a broad range of ligands, such as cells, proteins, and small molecules, and have been used as a molecular targeting element for incorporation into aptamer-drug conjugates (ApDCs) for targeted therapy. Because they can provide specificity at the molecular level, aptamers can be used to enhance the efficacy of experimental and/or commercial drugs in clinical applications (Tuerk and Gold, 1990; Fang and Tan, 2010; Sefah et al., 2010; Kamaly et al., 2012). Generally, tumor cells show a specific pattern of overexpressed membrane-associated proteins, particularly receptors. Many natural receptors are known to be significantly overexpressed in various cancer tissues and contribute to assembling nutrients for uncontrolled cancer growth and survival, tumor initiation, and stimulus for angiogenesis (Goel and Mercurio, 2013; Feigin et al., 2014). Traditional targeted therapy based on targeting molecules, including aptamers and antibodies, can recognize and directly bind to some specific overexpressed natural receptors on the diseased cell membrane and lead to release of anticancer drugs, achieving targeted killing of tumor cells with fewer side effects (Akhtar et al., 2014). However, many natural receptors associated with cancer are also expressed on noncancer cells, albeit at a lower level of expression, reducing the efficacy of targeted delivery and causing damage to healthy cells. The generation of artificial cell surface receptors, instead of natural receptors, offers the promise of increased specificity. In other words, artificial receptors could act as mimics drawing one hundred percent of targeted drug delivery to...
the cell of interest. Artificial receptors could be various types of molecules, such as proteins, polymers, or synthetic organic compounds, and could be used to promote efficient cellular uptake (Niikura et al., 2011), generate an artificial transmembrane signal transduction mechanism (Langton et al., 2017a, 2017b), and efficiently deliver therapeutics and probes (Hussey and Peterson, 2002; Boonyarattanakalin et al., 2004; Peterson, 2005; Sun et al., 2008; Hymel and Peterson, 2012). Artificial receptors can be produced on the cancer cell surface by using cancer cell characteristics and the tumor microenvironment (TME). Polydopamine (PDA) with low toxicity, excellent biocompatibility, and ultrastability (Liu et al., 2013; Han et al., 2016; Poirard et al., 2018) is widely known for its specific reactivity to the amino groups through Michael addition and Schiff base reaction (Lee et al., 2009; Liu et al., 2014; Li et al., 2017; Sileika et al., 2011). Thus, PDA with amino groups can be considered as a safe and efficient artificial receptor for anticancer drugs in the TME. In the last few years, TME, characterized by such features as ECM, exosome, or acidity, have been extensively employed as targets for targeted therapy (Joyce, 2005; Pickup et al., 2014; Paolicchi et al., 2016; Roma-Rodrigues et al., 2017; Yu et al., 2017; Iessi et al., 2018; Capello et al., 2019). The unique characteristics of the TME have a considerable impact on cancer progression, development, invasion, and metastasis (Hanahan and Coussens, 2012; Quail and Joyce, 2013; Joyce and Fearon, 2015; Spill et al., 2016). One such feature is the concentration of potassium ions in the TME, which is 5–10 times higher (40 mM) than that of healthy tissues (5 mM) (Eil et al., 2016). Hydrogen peroxide (H₂O₂) is also present in the TME in significant concentration (Sztawrowski and Nathan, 1991).

In this study, we produce polydopamine (PDA) on the tumor cell membrane surface as an artificial receptor through catalysis of dopamine using G-quadruplex DNAzyme, which only shows high catalytic activity in environments with high concentration of K⁺ and H₂O₂. Briefly, we employed AS1411 (Yang et al., 2016), through catalysis of dopamine using G-quadruplex DNAzyme, which only shows high catalytic activity in the presence of potassium ions. Next, potassium ion solution with final concentration of 40 mM was added into 2 M AS1411 solution to stabilize G quadruplex. Afterward, hemin was added into this mixture. Hemin binds with high affinity to G quadruplex, and after incubating the mixture at room temperature for 50 min, hemin-G quadruplex DNAzyme was produced. At this point, the created DNAzyme structure could achieve through H₂O₂ molecules abundantly available in the TME. This means that hemin-G quadruplex DNAzyme can be stabilized and exhibit (HRP)-like activity, but only in the tumor microenvironment, and we exploited this remarkable feature to generate PDA on tumor tissues. Because PDA can specifically react with amino groups, it can deposit on the cancer cell membrane and act as an artificial receptor, facilitating specific targeted delivery of anticancer drugs with amino-like cisplatin and protein drugs such as saporin.

RESULTS
Hemin-G Quadruplex DNAzyme Catalyzes Polydopamine Polymerization

In order to engineer the hemin-G quadruplex DNAzyme constructs, lipid-AS1411 (see detailed sequences in Supplemental Information Table S1) with G-rich sequence was synthesized to form stable G-quadruplex in the presence of potassium ions. Next, potassium ion solution with final concentration of 40 mM was added into 2 μM AS1411 solution to stabilize G quadruplex. Afterward, hemin was added into this mixture. Hemin binds with high affinity to G quadruplex, and after incubating the mixture at room temperature for 50 min, hemin-G quadruplex DNAzyme was produced. At this point, the created DNAzyme structure could exhibit predominant peroxidase-like activity and accelerate the production of PDA in the presence of hydrogen peroxide. Therefore, hydrogen peroxide (H₂O₂) with a final concentration of 500 μM was added to the constructed hemin-G quadruplex DNAzyme, followed by the addition of dopamine hydrochloride solution to the mixture. As illustrated in Scheme 1A, by generating G-quadruplex DNAzyme on the cell membrane and employing some specific characteristics of TME, we can accelerate the polymerization of dopamine to polydopamine specific to the cancer cell membrane as artificial receptors. PDA is widely known for its exceptional reactivity to amine groups; therefore, drugs with amino groups can react and attach to polydopamine. As shown in Scheme 1B, as a result of high extracellular concentration of K⁺ and H₂O₂ in the TME, PDA was only deposited on the membrane of cancer cells to then act as artificial receptors to deliver protein drugs and amino-containing small drugs with selectivity. This means that no PDA can be deposited on healthy cell membrane.

We first studied the catalytic ability of G quadruplex DNAzyme for PDA production. Because PDA can rapidly deposit on proteins, BSA, as the PDA deposition anchor point, was added to the mixture. Next, the produced PDA was measured by UV-VIS-NIR at 450 nm. As shown in Figure 1A, PDA is conventionally produced from oxidative polymerization of dopamine in a basic aqueous medium. However, this method is
considerably slow, and it takes a comparatively long time to produce a small amount of polydopamine. However, potassium ions play a key role in the construction of G-quadruplex DNAzyme, and hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) has an important role in rapidly catalyzing the production of PDA. In the presence of both hydrogen peroxide and potassium ions, a brown-black polydopamine can be produced after only 30 min following the addition of dopamine hydrochloride, indicating that hemin-G quadruplex DNAzyme can utilize the hydrogen peroxide to catalyze the polymerization of PDA. TEM imaging shows the production of polydopamine nanoparticles, and their rapid generation and deposition on BSA are shown in Figure 1B (Figures S1 and S2). In Figure 1C, the production of PDA was tested for the existence of various concentration of K\textsuperscript{+} (from 0 mM to 50 mM) and H\textsubscript{2}O\textsubscript{2} (from 0 \textmu M to 500 \textmu M) and the catalytic activity of DNAzyme in different conditions. As shown in the heatmap, by increasing the concentration of potassium ion and hydrogen peroxide, a higher amount of PDA was produced. Meanwhile, the corresponding photograph of produced PDA based on Figure 1C showed that the amount of produced polydopamine is directly correlated with the concentration of potassium ions and hydrogen peroxide (Figure S3, pH effect on PDA production).

**Polydopamine Generation and Deposition on the Cancerous Cell Membrane**

Encouraged by the precise deposition of PDA on BSA using hemin-G quadruplex DNAzyme, we further investigated the possibility of using PDA polymerization with the proposed method on cell membrane. To accomplish this, we employed cholesterol-AS1411 conjugates to anchor on the cell membrane (see Transparent Methods section within the Supplemental Information for further details). Because of hydrophobic interaction between cellular phospholipid layer and cholesterol, cholesterol-DNA conjugates could insert in cell membrane. We chose CCRF-CEM cells as a model cell line and added potassium ion (40 mM) and hydrogen peroxide (500 \textmu M) in cell culture media to mimic the TMEs with a high concentration of hydrogen peroxide and potassium ion. First, cholesterol-AS1411 conjugates were added to the cells and incubated for 40 min at 4°C; then a final concentration of 40 mM potassium ion solution was added and incubated for another 40 min at 4°C. For the next step, hemin was added to the mixture and stabilized DNAzyme was successfully generated. Finally, PDA was produced on the cell membrane after H\textsubscript{2}O\textsubscript{2} and dopamine addition. In the presence of H\textsubscript{2}O\textsubscript{2} and K\textsuperscript{+}, dopamine converts to polydopamine quickly such
that it can be localized and deposited on the cell membrane proteins (Figure S4). To evaluate whether the produced PDA on the cell membrane could be considered as an efficient artificial receptor, enhanced green fluorescent protein (EGFP) and FITC-7T-NH2 were chosen as model proteins. EGFP is a protein that exhibits bright green fluorescence and could be used to study the dynamic changes of cellular processes in living cells. Here, EGFP with high amine density, as the model protein, could be attached to deposited PDA on the cell membrane, generating a fluorescence signal with which to evaluate PDA production. Therefore, EGFP was added after the completion of PDA production in the cells, and then flow cytometry was employed to quantify and compare EGFP delivery efficiency. As shown in Figure 2A, an obvious shift in flow cytometry histogram occurs when the concentration of potassium ion and hydrogen peroxide is high enough to produce PDA on the cell membrane, acting as artificial receptors for our model protein and showing available PDA on the cell membrane by the amount of EGFP for attachment, as indicated by the uppermost peak in the histogram. For all other flow cytometry experiments, no apparent shift gives evidence of the amount of EGFP attached to the cell membrane, suggesting that only negligible amount resulted from the small amount of accessible PDA, which showed much lower fluorescence on the cells. Then, under the same conditions, a lower concentration of EGFP (100 nM) was applied, in turn leading to a lower amount of attached EGFP to the cell membrane and a smaller shift in flow cytometry histogram (Figure S5). Still, a distinct shift and fluorescence signal could be seen in the abundance of K⁺ and H₂O₂. After using EGFP as a model protein, an amino-containing fluorescence molecule was also used to perform as a small-molecule model, and it could recognize PDA production on the cell membrane. FITC-7T-NH2 is a short oligonucleotide sequence, with fluorescein isothiocyanate (FITC) directly coupled onto
the 5'-end and amino modifier coupled onto the 3'-end. The amino group in the sequence could attach to the produced PDA on the cell membrane, and a coupled FITC fluorescent molecule is on the other side. A fluorescence signal on the cell membrane can be detected by using flow cytometry. Accordingly, flow cytometry histograms confirmed that this model small-molecule could attach to cell membrane and generate fluorescence signal only in the presence of K⁺ and H₂O₂, which is consistent with the results of EGFP, indicating that PDA artificial receptors play a major role for targeted delivery of small molecules to the cells (Figure S6).

Next, confocal laser scanning microscopy (CLSM) imaging was used to monitor the targeting efficiency of PDA as an artificial receptor in the presence of K⁺ and H₂O₂. For this experiment, cells were fixed in 2% formalin solution for 7 min, stained with 4',6-diamidino-2-phenylindole (DAPI) to localize their nucleus, and washed prior to confocal microscopy observation. Confocal laser scanning microscopy images confirmed that samples incubated with both H₂O₂ and K⁺ exhibited a strong green fluorescence signal on the cell membrane, as well as in the cytoplasm of CCRF-CEM cells, indicating that EGFP not only bound to target CCRF-CEM cells, but were also internalized (Figure 2B). Based on the results shown in Figure 2, produced PDA can be employed as artificial receptor for targeted delivery of protein drugs to the cells in the presence of both K⁺ and H₂O₂ (Cell uptake analysis Figure S7).

**Deposited Polydopamine on the Cancerous Cell Membrane Act as Artificial Receptors for Targeted Drug Delivery**

Inspired by the well-defined delivery of FITC-7T-NH₂ and EGFP by utilizing PDA, we eventually explored the capacity of this artificial receptor to perform functional targeted drug delivery in cancer therapeutics and precise therapy. For this purpose, cisplatin, an anticancer and cytotoxic chemotherapeutic small drug with an amino group, was selected. Then, saporin, an anticancer protein drug that impedes protein synthesis with the aid of ribosome inactivation, was used. Potent cytotoxicity of chol-AS1411 and PDA production was then examined by using the MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxypyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)). CCRF-CEM cells (30,000) were washed and incubated with the desired concentration of cholesterol-AS1411 (from 0 μM to 5 μM), and MTS assay was employed to measure cell viability. As shown in Figure 3A, chol-AS1411 was not toxic to CCRF-CEM cells, even at concentration up to 5mM. Cytotoxicity effect of PDA production was also examined, and based on the MTS results in Figure 3B, even the addition of all reagents did not cause dramatic cytotoxicity under our experimental conditions, indicating excellent biocompatibility and applicability for using this method in the cell’s microenvironment. These results indicate that PDA production in TME does not have a toxic impact on cell viability; also, PDA’s deposition on the cell membrane did not affect the cell viability and
the membrane structure, as shown in Figure S4. In addition, in PDA degradation point of view, in vivo studies performed by Langer’s group have confirmed that polydopamines were almost entirely degraded after eight weeks and suggested that polydopamine could be degraded in vivo in a timely manner (Bettinger et al., 2009).

To evaluate targeted therapy efficiency based on PDA artificial receptor, saporin (0–10 μM), as a model protein drug, and cisplatin (0–750 μM), as the amino-containing model small-molecule drug, were exposed to CCRF-CEM cells right after the production of PDA on their cell membrane and then incubated at 37°C in 5% CO₂ for 6 h. Cells were then washed, and fresh RPMI-1640 complete medium was added to the cell’s solution. Culture medium was allowed to grow at 37°C in 5% CO₂ for 48 h, and, eventually, MTS assay was used for cytotoxicity determination. As demonstrated in Figures 3C and 3D, after saporin and cisplatin incubation, CCRF-CEM cells with the artificial receptor showed significant reduction of cell viability to 10%, whereas without generation of artificial receptor, no obvious cytotoxicity was observed for the CCRF-CEM cells (Figure S8, the cytotoxicity study also confirmed these results). Also, according to the results in Figures S9 and S10, the IC₅₀ of cisplatin decreased from 1,082.68 μM to 3.16 μM with artificial receptors, and for saporin, it decreased from 34.73 μM to 3.469 μM. To further investigate the PDA deposition on the cancerous and non-cancerous cell membrane, if both are available in tumor micro-environment, MDA-MB-231, a cancerous breast cell line, and MCF10A, a non-cancerous breast cell line, were employed. PDA was generated and deposited...
on both cell lines, and cisplatin was applied as amine-containing cytotoxic drug as described in Supplemental Information, and finally cell viability was evaluated using MTS assay. As it is shown in Figure 4, the cisplatin cytotoxicity is obviously higher in MDA-MB-231 cell line in the same exact condition with MCF10A. These results indicate that the higher protein density in cancerous cell could help the PDA to specifically deposit on their cell membrane compared with non-cancerous cells. Significantly, PDA artificial receptors delivered cisplatin and saporin to inhibit cell proliferation with higher efficiency than observed for cells without artificial receptors at any drug concentration level, further confirming a superior drug delivery efficiency using artificial receptors in biological settings. Besides, these results show that if PDA artificial receptors are available on the cancerous cell membranes, there is a considerable probability that the amine-containing drug cargo will deposit on the cells as soon as it is added to the TME and kills the cells significantly faster than there are no artificial receptors on the cells. Thus, it may be concluded that PDA can be produced and serves as an artificial receptor on the cell membrane for precise targeted delivery of anticancer drugs with amino groups, but only in the presence of K⁺ and H₂O₂. Moreover, to determine the specificity of the designed PDA artificial receptors with amino-containing drug in the living subject, additional in-vivo studies are needed.

Conclusion

In summary, we have successfully generated PDA as artificial receptors on the cancer cell membrane by employing specific TME features. Owing to the peroxidase-like activity of hemin-G quadruplex DNAzyme, polydopamine molecules were quickly produced and deposited on the cancer cell membrane to facilitate targeted delivery of anticancer drugs with amino groups. Taking advantage of the unique feature of cancer cells, their membrane and their microenvironment, only these artificial receptors were targeted by amino-containing drugs. By using saporin and cisplatin as two model drugs, we were able to realize much higher efficiency in inhibition of the cell proliferation in the presence of artificial receptors.

Limitation of the Study

The result of this study indicates that deposited PDA artificial receptors on the cancerous cell membrane could facilitate the delivery of amino-containing drugs. Further in vivo studies are needed to determine the specificity of the designed PDA artificial receptors in the living subjects’ complex environment and also to evaluate the physiological and biochemical characteristics of this system in order to ultimately develop potential therapeutic strategies using these artificial receptors.

Resource Availability

Lead Contact

Further information and requests should be directed to and will be fulfilled by the Lead Contact, Weihong Tan (tan@hnu.edu.cn).
Materials Availability
This study did not generate new unique reagents.

Data and Code Availability
All data produced or analyzed for this study are included in the published article and its Supplemental Information files.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101750.

ACKNOWLEDGMENTS
This work is supported by National Natural Science Foundation of China, China (NSFC 21827811).

AUTHOR CONTRIBUTIONS
H.SY. and Y.Y. contributed equally to this work.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: March 31, 2020
Revised: August 2, 2020
Accepted: October 27, 2020
Published: December 18, 2020

REFERENCES

Akhtar, M.J., Ahamed, M., Alhadiq, H.A., Alrokayan, S.A., and Kumar, S. (2014). Targeted anticancer therapy: overexpressed receptors and nanotechnology. Clin. Chim. Acta 436, 78–92.

Bettinger, C.J., Bruggeman, J.P., Misra, A., Borenstein, J.T., and Langer, R. (2009). Biocompatibility of biodegradable semiconducting melanin films for nerve tissue engineering. Biomaterials 30, 3050–3057.

Boonyarattanakalin, S., Martin, S.E., Dykstra, S.A., and Peterson, B.R. (2004). Synthetic mimics of small mammalian cell surface receptors. J. Am. Chem. Soc. 126, 16379–16386.

Capello, M., Vykoukal, J.V., Katayama, H., Banti, L.E., Wang, H., Kundnani, D.L., Aguilar-Bonavidés, C., Aguilar, M., Tripathi, S.C., Dhillon, D.S., et al. (2019). Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat. Commun. 10, 254.

Chari, R.V.J. (2008). Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98–107.

Edl, R., Vodnala, S.K., Clever, D., Klebanoff, C.A., Sukumar, M., Pan, J.H., Palmer, D.C., Gros, A., Yamamoto, T.N., Patel, S.J., et al. (2016). Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539.

Fang, X.H., and Tan, W.H. (2010). Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res. 43, 48–57.

Feigin, M.E., Xue, B., Hammell, M.C., and Mulhuswamy, S.K. (2014). G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc. Natl. Acad. Sci. U S A 111, 4191–4196.

Goel, H.L., and Mercurio, A.M. (2013). VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871–882.

Han, J., Park, W., Park, S.J., and Na, K. (2016). Photosensitizer-conjugated hyaluronic acid-shielded polydopamine nanoparticles for targeted photomediated tumor therapy. Acs Appl. Mater. Interfaces 8, 7739–7747.

Hanahan, D., and Coussens, L.M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322.

Hussey, S.L., and Peterson, B.R. (2002). Efficient delivery of streptavidin to mammalian cells: clathrin-mediated endocytosis regulated by a synthetic ligand. J. Am. Chem. Soc. 124, 6265–6273.

Hymel, D., and Peterson, B.R. (2012). Synthetic cell surface receptors for delivery of therapeutics and probes. Adv. Drug Deliv. Rev. 64, 797–810.

iScience 23, 101750, December 18, 2020

lessi, E., Logozzi, M., Mizzoni, D., di Raimo, R., Supuran, C.T., and Fais, S. (2018). Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 8, 2.

Joyce, J.A. (2005). Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513–520.

Joyce, J.A., and Fearon, D.T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80.

Kamaly, N., Xiao, Z.Y., Valencia, P.M., Radovic-Moreno, A.F., and Farokhzad, O.C. (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41, 2971–3010.

Langton, M.J., Keymeulen, F., Ciaccia, M., Williams, N.H., and Hunter, C.A. (2017a). Controlled membrane translocation provides a mechanism for signal transduction and amplification. Nat. Chem. 9, 426–430.

Langton, M.J., Scriven, L.M., Williams, N.H., and Hunter, C.A. (2017b). Triggered release from lipid bilayer vesicles by an artificial transmembrane signal transduction system. J. Am. Chem. Soc. 139, 15768–15773.

Lee, H., Rho, J., and Messersmith, P.B. (2009). Facile conjugation of biomolecules onto surfaces via mussel adhesive protein inspired coatings. Adv. Mater. 21, 431.
Li, J.W., Baird, M.A., Davis, M.A., Tai, W.Y., Zweifel, L.S., Waldorf, K.M.A., Gale, M., Rajagopal, L., Pierce, R.H., and Gao, X.H. (2017). Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. Nat. Biomed. Eng. 1, 0082.

Li, L., Chen, X.G., Cui, C., Pan, X.S., Li, X.W., Yazd, H.S., Wu, Q., Qiu, L.P., Li, J., and Tan, W.H. (2019). Aptamer displacement reaction from live-cell surfaces and its applications. J. Am. Chem. Soc. 141, 17174–17179.

Liu, X.S., Cao, J.M., Li, H., Li, J.Y., Jin, Q., Ren, K.F., and JI, J. (2013). Mussel-inspired polydopamine: a biocompatible and ultrastable coating for nanoparticles in vivo. ACS Nano 7, 9384–9395.

Liu, Y.L., Ai, K.L., and Lu, L.H. (2014). Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem. Rev. 114, 5057–5115.

Niikura, K., Nambara, K., Okajima, T., Kamitani, R., Aoki, S., Matsuo, Y., and Ijiro, K. (2011). Artificial polymeric receptors on the cell surface promote the efficient cellular uptake of quantum dots. Org. Biomol. Chem. 9, 5787–5792.

Paolicchi, E., Gemignani, F., Krstic-Demonacos, M., Dedhar, S., Mutti, L., and Landi, S. (2016). Targeting hypoxic response for cancer therapy. Oncotarget 7, 13464–13478.

Peterson, B.R. (2005). Synthetic mimics of mammalian cell surface receptors: prosthetic molecules that augment living cells. Org. Biomol. Chem. 3, 3607–3612.

Pickup, M.W., Mouw, J.K., and Weaver, V.M. (2014). The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243–1253.

Poinard, B., Neo, S.Z.Y., Yeo, E.L.L., Heng, H.P.S., Neoh, K.G., and Kah, J.C.Y. (2018). Polydopamine nanoparticles enhance drug release for combined photodynamic and photothermal therapy. ACS Appl. Mater. Interfaces 10, 21125–21136.

Quail, D.F., and Joyce, J.A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437.

Roma-Rodrigues, C., Raposo, L.R., Cabral, R., Paradinh, F., Baptista, P.V., and Fernandes, A.R. (2017). Tumor microenvironment modulation via Gold nanoparticles targeting malicious exosomes: implications for cancer diagnostics and therapy. Int. J. Mol. Sci. 18, 162.

Sefah, K., Shangguan, D., Xiong, X.L., O’donoghue, M.B., and Tan, W.H. (2010). Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 5, 1169–1185.

Sileika, T.S., Kim, H.D., Maniak, P., and Messersmith, P.B. (2011). Antibacterial performance of polydopamine-modified polymer surfaces containing passive and active components. ACS Appl. Mater. Interfaces 3, 4602–4610.

Spill, F., Reynolds, D.S., Kamm, R.D., and Zaman, M.H. (2016). Impact of the physical microenvironment on tumor progression and metastasis. Curr. Opin. Biotechnol. 40, 41–48.

Sun, Q., Cai, S., and Peterson, B.R. (2008). Selective disruption of early/recycling endosomes: release of disulfide-linked cargo mediated by a N-alkyl-3 beta-cholesterylamine-capped peptide. J. Am. Chem. Soc. 130, 10064.

Szatrowski, T.P., and Nathan, C.F. (1991). Production of large amounts of hydrogen-peroxide by human tumor-cells. Cancer Res. 51, 794–798.

Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment - ma ligands to bacteriophage-T4 DNA-polymerase. Science 249, 505–510.

Xuan, W.J., Peng, Y.B., Deng, Z.Y., Peng, T.H., Kuai, H.L., Li, Y.Y., He, J.X., Jin, C., Liu, Y.L., Wang, R.W., and Tan, W.H. (2018). A basic insight into aptamer-drug conjugates (ApDCs). Biomaterials 182, 216–226.

Yang, Y., Liu, J.J., Sun, X.Q., Feng, L.Z., Zhu, W.W., Liu, Z., and Chen, M.W. (2016). Near-infrared light-activated cancer cell targeting and drug delivery with aptamer-modified nanostructures. Nano Res. 9, 139–148.

Yang, Y., Zhu, W.J., Feng, L.Z., Cao, Y., Yi, X., Dong, Z.L., Yang, K., Tan, W.H., Liu, Z., and Chen, M.W. (2018). G-Quadruplex-Based nanoscale coordination polymers to modulate tumor hypoxia and achieve nuclear-targeted drug delivery for enhanced photodynamic therapy. Nano Lett. 18, 6862–6875.

Yu, T.C., Tang, B., and Sun, X.Y. (2017). Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med. J. 58, 489–496.

Zhu, G.Z., Niu, G., and Chen, X.Y. (2015). Aptamer-drug conjugates. Bioconjuk. Chem. 26, 2186–2197.
Supplemental Information

Precise Deposition of Polydopamine on Cancer Cell Membrane as Artificial Receptor for Targeted Drug Delivery

Hoda Safari Yazd, Yu Yang, Long Li, Lu Yang, Xiaowei Li, Xiaoshu Pan, Zhuo Chen, Jianhui Jiang, Cheng Cui, and Weihong Tan
Supporting Information
Figure S1. PDA in the presence of Bovine Serum Albumin (BSA), Related to Figure 1.

UV-VIS absorption spectra of the produced polydopamine (PDA) in the presence of different concentration of Bovine Serum Albumin (BSA).
Figure S2. Transmission Electron Microscopy (TEM) image of PDA nanoparticles, Related to Figure 1.

A and B shows the TEM images of a mixture that contains BSA, which confirms that PDA molecules are confined near BSA. C and D shows the TEM images of a mixture that does not contain BSA and PDA molecules quickly diffuse away and did not generate dark spots.
Figure S3. Absorbance of PDA solutions resulting from different initial pH values, Related to Figure 1.

To investigate the pH effect on the synthesis of PDA, we generated the PDA as it is described before and the initial pH adjusted to the required values by adding HCl and/or NaOH using a calibrated pH meter.
Figure S4. Microscope image of deposited PDA particles on the cell membrane, Related to Figure 2.

A) the control, B) PDA produced on the cell membrane as it is described in Supporting Information.
Figure S5. PDA Produced and Deposited on Cell Membrane, Related to Figure 2.

Flow cytometry histogram of CCRF-CEM cells treated with a low concentration of EGFP (100 nM), which leads to the low amount of attached EGFP to the cell membrane, as well as a smaller shift in flow cytometry histogram, rather than higher concentration of EGFP.
Flow cytometry histogram of CCRF-CEM cells treated with various reagents. FITC-7T-NH2, which is a short oligonucleotide sequence coupled directly to fluorescein isothiocyanate (FITC) and amino modifier, was used as the amino-containing detection molecule. Results show FITC-7T-NH2 attached to the deposited PDA on cell membrane, but only in the presence of both K⁺ and H₂O₂ reagents, generating a good amount of fluorescence signal on the cell membrane and a shift in flow cytometry histogram.
Figure S7. Cell uptake of EGFP as the protein model drug investigated using flow cytometry, Related to Figure 2.

Cell uptake of EGFP (50 nm) as the protein model drug investigated using flow cytometry. After PDA generated on the cell membrane, EGFP (50 nM) added as protein model drug owing to its fluorescence activity. Then the cells were incubated at 4 ºC for 1 hour and after 3 washing steps, the medium added to them and incubated at 37 ºC for 2h, 4h, 6h, and 8h. Before flow cytometry analysis, the cells were treated by trypsin for 3 minutes to remove all remaining EGFP on the cell membrane. Then after addition of medium and centrifugation, the cells were washed two times and trypsin was removed and finally flow cytometry analysis conducted to examine the cell uptake of the model drug.
Figure S8. Cytotoxicity of CCRF-CEM cells treated with various reagents followed by verification of cytotoxicity by LDH toxicity assay, Related to Figure 3.

The error bars represent the standard deviation of three parallel experiments. A) Cells treated with different concentration of Chol-AS1411. B) Cells treated with PDA reagents, Group Dop: dopamine only; Group Control: dopamine and hemin-lipid-AS1411 without K+ and H2O2. C) Cells treated with different concentration of saporin (with/without artificial receptor). D) Cells treated with different concentration of cisplatin (with/without artificial receptor). The “Without PDA” labels in Figure 8C and 8D contains all the compounds just dopamine, and all the reaction condition kept exactly same with the “With PDA” wells.
Figure S9. Cell viability of CCRF-CEM cells treated with different concentration of cisplatin, Related to Figure 3.

Cell viability of CCRF-CEM cells treated with different concentration of cisplatin (with/without artificial receptor), followed by verification of cell viability by MTS assay. The error bars represent the standard deviation of three parallel experiments.
Figure S10. Cell viability of CCRF-CEM cells treated with different concentration of saporin, Related to Figure 3.

Cell viability of CCRF-CEM cells treated with different concentration of saporin (with/without artificial receptor), followed by verification of cell viability by MTS assay. The error bars represent the standard deviation of three parallel experiments.
| Name          | Detailed Sequence Information                      |
|--------------|---------------------------------------------------|
| 10T-AS1411   | TTT TTT TTT TGG TGG TGG TGG TGG TGG TGG TGG      |
| Chol-AS1411  | Cholesterol - TTT TTT TTT TGG TGG TGG TGG TGG TGG |
| FITC-7T-NH₂  | FITC - TTT TTT T - NH₂ - TTT TTT TTT TTT TTT     |
|              | TTT TT                                          |
Transparent Methods

1. Experimental Procedures

1.1 Materials

All used reagents were purchased from Thermo Fisher Scientific and Sigma-Aldrich unless otherwise stated. All DNA synthesis and modification reagents were purchased from Glen Research Corp. and ChemGenes Corp. DNA grade water from Fisher Scientific was used in all experiments, and phosphate-buffered saline (1X PBS) was purchased from Fisher Scientific. Also, 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES buffer, 1M) was purchased from Thermo Fisher Scientific. The hemin stock solutions (5 μM) were made in dimethyl sulfoxide (DMSO) and stored in the dark and frozen at -20 °C.

1.2 Purification and Synthesis of Oligonucleotides

All oligonucleotides were synthesized with an ABI 3400 DNA synthesizer (Applied Biosystems, Inc., Foster City, CA) established on solid-state phosphoramidite chemistry at a 1 μmol scale. All synthesis started from controlled-pore glass (CPG) column and Cholesteryl-TEG phosphoramidite, and amino modifier coupled immediately onto the 3’-end of oligonucleotides. Deprotection procedure of all DNA sequences was carried out according to the instructions prepared by the manufacturer (Glen Research Corp.). Afterwards, by adding 2.5 times volume of cold ethanol and 1/10 volume of 3 M sodium chloride, DNA sequences were precipitated and placed in a -20°C freezer for 40 minutes. Later, by centrifuging for 20 minutes at 4,000 rpm, all precipitated DNA sequences were collected.

Purification of all deprotected DNA has been done by using reverse-phase high-performance liquid chromatography (HPLC) (ProStar, Varian, Walnut Creek, CA, USA) with a C18 column.
(Econosil, 5µM, 250 X 4.6 mm). Acetonitrile and 0.1 M triethylamine acetate (TEAA) aqueous solution was used as the mobile phase in HPLC. After HPLC, all collected samples were vacuum dried, and sequences with DMT were treated with 80% acetate acid for 20 minutes at room temperature and finally precipitated by using 5/4 times volume of ice-cold ethanol and 1/10 volume of 3 M sodium chloride.

All sequence concentrations were quantified by measuring the absorbance at 260 nm using a UV-1800 UV spectrophotometer (Shimadzu Corp.).

1.3 Cell Culture

The CCRF-CEM (CCL-119 T-cell, human acute lymphoblastic leukemia), MDA-MB-231, and MCF10A cell lines was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). RPMI 1640 medium (Gibco®, Life Technologies, Carlsbad, CA) supplemented by 10% fetal bovine serum (FBS, heat inactivated) (Gibco®, Life Technologies, Carlsbad, CA) and 1% penicillin-streptomycin (PS) (Life Technologies, Carlsbad, CA) were used to culture CCRF-CEM cells in humidified atmosphere containing 5% CO₂ at 37 °C. DMEM medium (Gibco®, Life Technologies, Carlsbad, CA) supplemented by 10% fetal bovine serum (FBS, heat inactivated) (Gibco®, Life Technologies, Carlsbad, CA) and 1% penicillin-streptomycin (PS) (Life Technologies, Carlsbad, CA) were used to culture MDA-MB-231 and MCF10A cells in humidified atmosphere containing 5% CO₂ at 37 °C.

1.4 Polydopamine Production

After synthesis and purification of the 10T-AS1411 probe, a 40 µL solution (10 µM) was heated at 95 °C for 5 minutes and then cooled to room temperature gradually before use. Then K⁺ ion
solution (40 μL, 200 mM) was added to the probe solution, and DNA sequences were allowed to fold into G-quadruplex conformation at room temperature for 40 minutes. Next, to produce hemin-G quadruplex DNAzyme, 20 μL of hemin solution (5 μM) were added to the mixture and incubated for 50 minutes at room temperature. Then hydrogen peroxide (H₂O₂) (40 μL, 2.5 mM) with final concentration of 500 μM was added to the constructed hemin-G quadruplex DNAzyme, and 2 minutes later, dopamine hydrochloride solution (60 μL, 100mM) was added to the mixture. Polydopamine was checked 30 minutes later by measuring absorbance at 450 nm with a microplate reader (CLARIOstar; BMG Labtech).

1.5 Transmission Electron Microscopy (TEM) Analysis

Ten microliters of sample were dropped on a carbon-coated copper grid for two minutes. Then a piece of filter paper was used to wick away extra solution, and the grid was air dried for TEM analysis. The grid was observed on a Hitachi H7000 microscope. The image was achieved with a slow-scan charge-coupled device (CCD) camera (Veleta 2k x 2k).

1.6 Flow Cytometry

Chol-AS1411 probe solution was heated at 95 °C for 5 minutes and then cooled to room temperature gradually before use. CCRF-CEM cells with a concentration of 2 X 10⁵ cells/well were washed with ice-cold 50 mM HEPES buffer. After centrifugation at 1300 rpm for 3 minutes, cells were incubated with the chol-AS1411 solution in HEPES buffer (final concentration = 2 μM) at 4 °C for 40 minutes. Then K⁺ ion solution, hemin, and H₂O₂ were added to the cells with the same procedure as that of the last step. After dopamine hydrochloride solution was added, the cells were incubated at 4 °C for 30 minutes. Then, cells were washed
twice by ice-cold 50 mM HEPES buffer to remove excess probes and polydopamine. In this step, the enhanced green fluorescent protein (EGFP) (100 nM or 500 nM) or FITC-NH₂ Probe (3 µM) was added to the cells to detect the production of polydopamine, and after 20 minutes, the cells were washed three times and resuspended in HEPES buffer for flow cytometry analysis.

EGFP and FITC fluorescence were measured by BD™ Acuuri C6 flow cytometer, and 10,000 events were counted by setting EGFP and FITC channel under the same parameters. FlowJo software was used for data analysis.

1.7 Confocal Microscopy Study

Confocal laser scanning microscopy (CLSM) imaging was used to monitor the production of polydopamine. To ready cells for imaging, the procedure was the same as that for flow cytometry, but the concentration of EGFP increased to 2 µM. After adding EGFP and waiting for 20 minutes, the cells were washed three times and resuspended in 2% formalin solution to fix the cells for 7 minutes, and they were removed again, followed by the addition of 4′,6-diamidino-2-phenylindole (DAPI). After 10 minutes, the cells were washed for fluorescence imaging with a Leica TCS SP5 confocal microscope. All images were analyzed finally with LAS AF.

1.8 Cell Viability Study

MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was used for all cell cytotoxicity experiments, and microplate reader (CLARIOstar, BMG Labtech) used to collect the absorbance of cells at 490 nm.
Cytotoxicity of chol-AS1411 was measured initially. CCRF-CEM cells (30,000) were washed and allocated to wells of a 96-well flat bottom, and 100 μL of cold 50 mM HEPES buffer with the desired concentration of cholesterol-AS1411 (from 0 μM to 5 μM) were added and incubated at 37 °C in 5% CO2 for 3 hours. After removing the supernatant, the cells were washed three times with ice-cold 50 mM HEPES buffer. Then the cells were resuspended in RPMI-1640 complete medium (1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) and 10% Fetal Bovine Serum (FBS)) and incubated for 48 hours. After washing the cells, MTS reagent (20 μL) was added to each well with 100 μL of fresh medium and incubated for 1 hour. Next, the absorbance was collected and normalized to the absorbance of just fresh medium and MTS reagent. Concentrations < 5μM of chol-AS1411 are not toxic to CCRF-CEM cells.

The cytotoxicity of producing PDA was measured afterward. CCRF-CEM cells (30,000) were washed and allocated to wells of a 96-well flat bottom, and polydopamine was produced in vitro as discussed before. After dopamine hydrochloride solution was added, the cells were incubated at 4 °C for 30 minutes. Then, cells were washed by ice-cold 50 mM HEPES buffer. Next, they were resuspended in RPMI-1640 complete medium and incubated for 48 hours, followed by MTS assay as the last step. The production of polydopamine by using hemin-G quadruplex DNAzyme was not cytotoxic to CCRF-CEM cells.

To investigate the potency of the artificial receptor for targeted drug delivery, 30,000 CCRF-CEM cells were washed and allocated to wells of a 96-well flat bottom, and polydopamine was produced in vitro as discussed before. After dopamine hydrochloride solution was added, the cells were incubated at 4 °C for 30 minutes. Then, cells were washed by ice-cold 50 mM HEPES buffer and gradient concentration of saporin (0 to 10 μM) and cisplatin (0 to 750 μM) in RPMI-1640 complete medium was added to the cell solution and then incubated at 37 °C in 5% CO2
for 6 hours. Cells were then washed, and fresh RPMI-1640 complete medium added again to the cell solution, followed by at 37 °C in 5% CO2 for 48 hours. After washing the cells, MTS reagent (20 μL) was added to each well with 100 μL of fresh medium and incubated for 1 hour. Next, the absorbance was collected and normalized to the absorbance of just fresh medium and MTS reagent. All steps were performed on cells in the same manner without the artificial receptor. However, the reagents to produce PDA were not added. The IC50 values were calculated as the concentrations reducing proliferation of cells by 50% and are given as the means and errors of 3 independent experiments (Figure S3).

1.9 Cytotoxicity Study
The cytotoxicity effect of PDA production via LDH cytotoxicity assay was investigated. In this cytotoxicity assay, the cell death measured by cell-free supernatants from cells in culture and then extra absorption of PDA could not affect its result. Cell death was evaluated via measuring the release of cytoplasmic Lactate Dehydrogenase (LDH) isoenzymes from damaged cells using the LDH toxicity assay kit, according to the manufacturer's instructions (Thermo Fisher Scientific). Briefly, the cells treated exactly same as it described in “Cell Viability Study” section above, but instead of MTS cytotoxicity assay, LDH cytotoxicity assay was used. 50μL of each sample medium was transferred to a 96-well flat bottom plate and 50μL of LDH reaction mixture was added to each well. After 30 minutes incubation at room temperature, 50 μL of stop solution added to each well. The final absorbance was measured at 490 nm and all experiments were conducted in triplicate.